title: Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults.
abstract: BACKGROUND
  Atopic dermatitis (AD) is a common inflammatory skin disease. Methotrexate (MTX) was suggested as an effective treatment option in cases of moderate-to-severe atopic dermatitis. This study assessed the efficacy and safety of treatment with low weekly doses of methotrexate for moderate-to-severe AD in adults.
  
  
  METHODS
  Twenty adult patients with moderate-to-severe AD were included in this retrospective study. Those patients were unresponsive to topical treatments, antihistamines and at least one of the second-line treatments. MTX in low weekly doses of 10-25 mg was administered orally or intramuscularly with folic acid supplementation 5 mg per week for at least 8-12 weeks. The response to treatment was evaluated by change in SCORAD (SCORing Atopic Dermatitis), DLQI (Dermatology Quality of Life Index) and the global assessment of the clinical response score.
  
  
  RESULTS
  After 8-12 weeks of treatment, we observed an objective response in most patients. There were 16 responders and 4 non-responders. The mean SCORAD and DLQI decreased by 28.65 units (44.3%) and 10.15 units (43.5%), respectively. The first improvement was observed after a period ranging from 2 weeks to 3 months (mean 9.95 w +/- 3.17). Treatment was more effective in adult onset AD than in childhood onset. Tolerance of treatment was good. However, nausea and an increase of liver enzymes were observed in 5 patients and 3 of them required a transient discontinuation of MTX. One patient developed peripheral neuropathy, which was resolved several weeks after the discontinuation of MTX.
  
  
  CONCLUSIONS
  MTX seems to be an effective and safe second-line treatment for patients with moderate-to-severe atopic dermatitis. A randomized, controlled study is warranted.
authors: Sheba Medical Center - Dermatology Department, Tel-Hashomer, Ramat-Gan, Israel. annaly@bezeqint.net
authors: A
authors: A
authors: Lyakhovitsky
authors: A
authors: A
authors: Barzilai
authors: R
authors: R
authors: Heyman
authors: S
authors: S
authors: Baum
authors: B
authors: B
authors: Amichai
authors: M
authors: M
authors: Solomon
authors: D
authors: D
authors: Shpiro
authors: H
authors: H
authors: Trau
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D007166:Immunosuppressive Agents; D005492:Folic Acid; D008727:Methotrexate